Patient engagement in clinical trials is the practice of involving patients, patient advocates, and caregivers as active partners in how a trial is designed and conducted — not merely as the subjects who are enrolled in it. It covers input into protocol design, outcome selection, informed-consent language, and the burden a study places on participants, contributed before and during the trial rather than collected only as data once it is underway.
This is a distinct practice from two related but narrower mechanisms already covered elsewhere on this site: a Community Advisory Board (CAB), which is a specific standing governance structure, and an FDA Diversity Action Plan, which is a specific statutory recruitment-diversity filing requirement. Patient engagement is the broader practice that CABs are one institutional form of, and that good Diversity Action Plans typically draw on.
What Patient Engagement Means, and What It Doesn’t
Research-engagement terminology distinguishes several related activities that are easy to conflate:
- Participation — taking part in a study as an enrolled subject: consenting, receiving an intervention, providing data.
- Engagement (sometimes called involvement) — contributing as a partner to how the research itself is planned, conducted, and disseminated, independent of whether that person is also a participant.
The UK’s NIHR/INVOLVE framework, described on this site’s Patient and Public Involvement (PPI) term, draws this same line: involvement means active partnership in the research process itself, while participation means taking part as a research subject. Patient engagement in the US clinical-trials context maps onto the same distinction, most explicitly operationalized by the Patient-Centered Outcomes Research Institute (PCORI), which requires the studies it funds to involve patient partners — people who bring lived experience to a study’s design, conduct, and interpretation, distinct from the study’s enrolled subjects.
Patient engagement is also distinct from patient recruitment. Recruitment is the operational process of identifying and enrolling eligible participants once a trial is already designed; engagement happens upstream of that, shaping what the trial asks, how it defines success, and what it will actually ask participants to do.
Why It Matters
The rationale for patient engagement is that people who will actually experience a trial’s burdens and outcomes are positioned to catch design problems that clinical and regulatory expertise alone can miss: endpoints that don’t reflect what matters to patients, visit schedules or procedures that are unrealistic for the target population, consent language that is technically accurate but not actually comprehensible, and eligibility criteria that unintentionally exclude the people the treatment is meant to help. PCORI’s foundational premise is that comparative-effectiveness research is more likely to produce evidence patients and clinicians actually use in decisions when patients have shaped what questions the research asks in the first place.
Core Mechanisms
Patient engagement is not one specific structure but a set of mechanisms an organization can use in combination:
Patient Advisory Boards and Councils
A patient advisory board (or council) is a standing or study-specific group of patients, former participants, or patient advocates convened to review protocol drafts, consent materials, and recruitment messaging, and to flag burden or feasibility issues before a study opens. Unlike a Community Advisory Board, which is typically anchored to a defined community or trial network site (the model most associated with NIAID-sponsored HIV/AIDS trial networks), a patient advisory board is organized around the patient population or condition a trial addresses and may operate across sites or even across a sponsor’s broader portfolio.
PCORI’s Engagement Rubric
PCORI’s Engagement Rubric, developed from a literature synthesis and review with PCORI’s Advisory Panel on Patient Engagement, organizes engagement activities across three phases of a research project: the planning phase (identifying research topics, refining questions, selecting outcomes), the conducting phase (participating in study implementation, interpreting findings), and the dissemination phase (co-authoring or reviewing outputs, disseminating results to affected communities). It is one of the most widely cited practical frameworks for what “meaningful” engagement looks like at each stage, rather than treating engagement as a single one-time consultation.
Patient-Reported Outcomes in Protocol Design
A specific, high-value engagement mechanism is involving patients in selecting or validating patient-reported outcome (PRO) measures before a protocol is finalized — confirming that an instrument captures what patients themselves consider a meaningful change, not only what is easiest to measure. This overlaps with FDA’s own Patient-Focused Drug Development (PFDD) work, discussed below, which addresses how patient experience data and clinical outcome assessments should be selected and incorporated into regulatory endpoints.
Plain-Language and Consent Co-Design
Patient partners are also commonly used to review and simplify informed-consent forms and recruitment materials, since a document drafted for regulatory completeness is not automatically comprehensible to the population it is meant to inform. See this site’s guide on plain-language summaries for the related practice of translating study results, not just consent documents, into accessible language.
Patient Engagement vs. a Community Advisory Board
These are frequently confused because both put patients or community members in an advisory role, but they differ in scope and origin:
- A Community Advisory Board is a specific, usually standing governance structure tied to a study, site, or trial network, historically rooted in HIV/AIDS research and NIAID’s 1990s community-input model. It represents a community or site’s interests as a body.
- Patient engagement is the broader practice or philosophy of involving patients as research partners, of which a CAB is one institutional form. A trial can practice patient engagement through a patient advisory board, PRO co-design, or PCORI-style partnership without necessarily having a CAB, and a CAB’s community-representation role does not by itself satisfy every form of patient-centered engagement (for example, PRO selection or consent-language review).
Patient Engagement vs. FDA Diversity Action Plans
These serve different purposes and sit in different parts of trial planning:
- An FDA Diversity Action Plan is a specific statutory requirement, added by the Food and Drug Omnibus Reform Act of 2022 (FDORA), under which sponsors of certain pivotal drug and device trials must submit enrollment goals broken out by age, sex, race, and ethnicity, along with a rationale and a plan for meeting them. It is a regulatory filing obligation with defined content requirements.
- Patient engagement is not a filing requirement at all — it is a design and conduct practice. The two intersect in practice: patient advisory input on recruitment barriers, realistic eligibility criteria, and site accessibility can directly inform whether a sponsor’s Diversity Action Plan enrollment goals and outreach strategy are actually achievable, rather than being numbers set without input from the populations they target.
Regulatory and Funder Landscape
Patient engagement is reinforced, though not uniformly mandated, across several regulatory and funder frameworks:
- FDA’s Patient-Focused Drug Development (PFDD) initiative, which began under the FDA Safety and Innovation Act (2012) and was expanded under the 21st Century Cures Act (2016) and FDA Reauthorization Act (2017), commits FDA to a four-part methodological guidance series on collecting and using patient experience data in regulatory decision-making. The first guidance in the series, on collecting comprehensive and representative patient input, was finalized in June 2020; the remaining guidances address identifying what matters to patients and selecting or incorporating clinical outcome assessments into trial endpoints. This is a framework for how patient input should inform outcome measures and regulatory review, distinct from the enrollment-diversity focus of a Diversity Action Plan.
- PCORI requires meaningful patient and stakeholder engagement as a condition of its own research funding, using its Engagement Rubric as the practical reference for applicants.
- UK/NIHR standards — the UK Standards for Public Involvement (2019) referenced on this site’s PPI term set out six standards (inclusive opportunities, working together, support and learning, governance, communications, impact) that function as the closest UK analogue to a patient-engagement quality framework, though PPI is broader than clinical trials specifically.
No single US regulation currently mandates patient engagement the way FDORA mandates a Diversity Action Plan for covered trials — engagement is driven more by funder requirements (PCORI), FDA guidance encouraging it, and sponsor practice, than by a single binding rule.
Building a Patient Engagement Plan
Practical steps a sponsor, site, or research team can take to build engagement into a trial rather than treating it as an afterthought:
- Engage before the protocol is finalized. Input on eligibility criteria, visit burden, and outcome selection is far more valuable pre-protocol than as a post-hoc review of a document already locked for IRB submission.
- Define the engagement mechanism explicitly — a patient advisory board, individual patient partners embedded in the study team, or a PCORI-style structured engagement plan — rather than an informal, undocumented consultation.
- Compensate patient partners fairly for their time, consistent with the same ethical and IRB-review considerations that govern other forms of research compensation; see this site’s guide on clinical trial participant payments for the adjacent (but distinct) topic of compensating enrolled subjects.
- Validate patient-reported outcome measures with the target population before finalizing the statistical analysis plan, not after data collection has begun.
- Document engagement activities and their effect on the protocol, both because funders such as PCORI expect it and because it is the evidence that engagement was substantive rather than symbolic.
- Distinguish, in the protocol and any public materials, which advisory structures are in place — a patient advisory board, a Community Advisory Board, or both — and what each is actually responsible for, so the two are not treated as interchangeable.
Frequently Asked Questions
Is patient engagement the same as informed consent?
No. Informed consent is the process by which an individual agrees to participate as a research subject, based on disclosure of risks, benefits, and procedures. Patient engagement happens upstream of and alongside consent — it is about patients shaping the study itself, including, in some cases, the design and clarity of the consent process.
Do all clinical trials require a patient engagement plan?
No single US regulation requires one across the board. Funders such as PCORI require it as a condition of funding, and FDA guidance encourages incorporating patient experience data into outcome selection, but there is no blanket statutory mandate comparable to the FDORA Diversity Action Plan requirement for covered pivotal trials.
Can a Community Advisory Board fulfill patient-engagement expectations on its own?
Partially. A CAB provides ongoing community-level input and is a genuine, well-established form of engagement, but it is organized around a community or site rather than around specific tasks like PRO selection or consent-language review. Many sponsors use a CAB alongside, not instead of, a patient advisory board or PCORI-style structured engagement plan.
Does patient engagement help satisfy FDA Diversity Action Plan requirements?
Not directly — a Diversity Action Plan is a specific regulatory filing with defined content requirements under FDORA. Patient engagement is not a substitute for it. In practice, though, patient advisory input on recruitment barriers and site accessibility often makes a Diversity Action Plan’s enrollment goals more realistic and achievable.
